logo
AAT Bioquest

Deoxycholic acid-iFluor® 647 conjugate

Deoxycholic acid, also known as cholanoic acid is a bile acid. Deoxycholic acid-iFluor® 647 conjugate is a red fluorescent derivative of deoxycholic acid. It is an iFluor® 647-labeled bile acid derivative that closely parallels the cellular binding and uptake properties of deoxycholic acid. It is a divalent 'unipolar' anionic fluorescent bile salt analog that might offer a potentially useful probe for studying cellular mechanisms of deoxycholic acid at the hepatocellular level. Deoxycholic acid-iFluor® 647 conjugate can be used as a tool for the visualization of bile acid transport for the samples that have either strong blue or green fluorescence since its strong red fluorescence is well separated from blue or green fluorescence. Deoxycholic acid is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria. The two primary bile acids secreted by the liver are cholic acid and chenodeoxycholic acid. Deoxycholic acid, under the brand name Kybella, is approved by the FDA for reducing moderate-to-severe fat below the chin. When injected into submental fat, deoxycholic acid helps destroy fat cells.

Spectrum

References

View all 50 references: Citation Explorer
Cationic nanoparticles self-assembled from amphiphilic chitosan derivatives containing poly(amidoamine) dendrons and deoxycholic acid as a vector for co-delivery of doxorubicin and gene.
Authors: Chen, Shanshan and Deng, Junjie and Zhang, Li-Ming
Journal: Carbohydrate polymers (2021): 117706
Deoxycholic Acid and Lithocholic Acid Alleviate Liver Injury and Inflammation in Mice with Klebsiella pneumoniae-Induced Liver Abscess and Bacteremia.
Authors: Zheng, Yahong and Yue, Chengcheng and Zhang, Hui and Chen, Haoran and Liu, Yanyan and Li, Jiabin
Journal: Journal of inflammation research (2021): 777-789
Efficacy and safety of injectable deoxycholic acid for submental fat reduction: a systematic review and meta-analysis of randomized controlled trials.
Authors: Cunha, Karin Soares and Lima, Flávia and Cardoso, Roberta Marques
Journal: Expert review of clinical pharmacology (2021): 383-397
Free Deoxycholic Acid Exacerbates Vascular Calcification in CKD through ER Stress-Mediated ATF4 Activation.
Authors: Miyazaki-Anzai, Shinobu and Masuda, Masashi and Shiozaki, Yuji and Keenan, Audrey L and Chonchol, Michel and Kremoser, Claus and Miyazaki, Makoto
Journal: Kidney360 (2021): 857-868
pH-sensitive chitosan-deoxycholic acid/alginate nanoparticles for oral insulin delivery.
Authors: Zhang, Ya-Wen and Tu, Ling-Lan and Tang, Zhan and Wang, Qiao and Zheng, Gao-Li and Yin, Li-Na
Journal: Pharmaceutical development and technology (2021): 1-10
Page updated on October 12, 2024

Ordering information

Price
Unit size
Catalog Number36705
Quantity
Add to cart

Additional ordering information

Telephone1-800-990-8053
Fax1-800-609-2943
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Request quotation

Physical properties

Molecular weight

1253.63

Solvent

DMSO

Spectral properties

Correction Factor (260 nm)

0.03

Correction Factor (280 nm)

0.03

Correction Factor (656 nm)

0.0793

Extinction coefficient (cm -1 M -1)

2500001

Excitation (nm)

656

Emission (nm)

670

Quantum yield

0.251

Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22

Storage

Freeze (< -15 °C); Minimize light exposure
UNSPSC12171501
Product Image
Product Image
Gallery Image 1